Finance

Lists
1CYTK:BIT
Cytokinetics, Inc.
€64.32
-4.94%
(-3.34) 1D
Aug 28, 5:26:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 1CYTK...
Open
€64.32
High
€64.32
Low
€64.32
Mkt. cap
10.02B
Avg. vol.
9.00
Volume
48.00
52-wk high
€78.84
52-wk low
€30.60
No. of employees
673
Open
€64.32
High
€64.32
Low
€64.32
Mkt. cap
10.02B
Avg. vol.
9.00
Volume
48.00
52-wk high
€78.84
52-wk low
€30.60
No. of employees
673
News stories
From web sources and news partners
Profile
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function. Wikipedia
About Cytokinetics, Inc.
CEORobert I. Blum | Robert I. Blum
Employees673
Founded1997
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitecytokinetics.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.94M
17.76M
19.36M
28.62M
Cost of goods sold
99.23M
104.40M
98.08M
103.40M
Cost of revenue
99.23M
104.40M
98.08M
103.40M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
69.46M
91.72M
104.90M
104.40M
Operating expense
69.46M
91.72M
104.90M
104.40M
Total operating expenses
168.69M
196.12M
202.97M
207.80M
Operating income
-166.76M
-178.37M
-183.62M
-179.17M
Other non operating income
-2.10M
14.20M
-100.00K
1.30M
EBT including unusual items
-306.18M
-183.03M
-206.03M
-198.76M
EBT excluding unusual items
-184.93M
-183.03M
-206.03M
-198.76M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-306.18M
-183.03M
-206.03M
-198.76M
Net profit margin
-15,814.98%
-1,030.87%
-1,064.48%
-694.39%
Earnings per share
-1.54
-1.50
-1.67
-1.50
Interest and investment income
10.25M
11.47M
11.02M
13.94M
Interest expense
-26.32M
-30.34M
-33.34M
-34.83M
Net interest expenses
-16.07M
-18.86M
-22.31M
-20.89M
Depreciation and amortization charges
-
-
-
-
EBITDA
-164.08M
-175.50M
-180.24M
-175.54M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps